首页 | 本学科首页   官方微博 | 高级检索  
检索        

罗格列酮和瑞格列奈治疗2型糖尿病疗效观察
引用本文:左晶,马春野.罗格列酮和瑞格列奈治疗2型糖尿病疗效观察[J].吉林医学,2008,29(17):1419-1420.
作者姓名:左晶  马春野
作者单位:吉林省人民医院内分泌一疗区,吉林大学第一医院心外科
摘    要:目的:探讨罗格列酮和瑞格列奈治疗2型糖尿病的疗效。方法:94例2型糖尿病患者口服罗格列酮4mg-8mg,1次/d,瑞格列奈1mg-4mg,3次/d,治疗16周,监测治疗前后空腹、餐后2h血糖(FBG、PBG)、糖化血红蛋白(HbA1c)、空腹血浆胰岛素(FINS)、低密度脂蛋白(LDL)、肝、肾功能。结果:FBG下降4.98mmol/L,PBG下降8.05mmol/L,HbA1c下降1.93%,FINS下降11.0μU/ml,LDL下降0.12mmol/L,较与治疗前均显著下降(P〈0.001及P〈0.05),且均未发生低血糖事件及肝肾功能异常(P〉0.05)。结论:罗格列酮和瑞格列奈治疗2型糖尿病具有降糖、降脂、降低血浆胰岛素水平、安全性及耐受性良好的特点。

关 键 词:罗格列酮  瑞格列奈  糖尿病  胰岛素抵抗

Therapeutic observation of Rosiglitazone and Repaglinide in the treatment of type 2 diabetes mellitus
ZUO Jing,MA Chun-ye.Therapeutic observation of Rosiglitazone and Repaglinide in the treatment of type 2 diabetes mellitus[J].Jilin Medical Journal,2008,29(17):1419-1420.
Authors:ZUO Jing  MA Chun-ye
Institution:ZUO Jing1,MA Chun-ye2
Abstract:Objective To explore the therapeutic effect of Rosigitazone and Repaglinide in treating type 2 diabetes mellitus.Method Fasting plasma glucose(FPG) pre and post medication,postprandial glucose following meal 2 hours later(PG2H),glycosylated hemoglobin(GHbA1c),fasting insulin(FINS),low density lipoprotein(LDL) and the functions of liver and renal were monitored in 94 type 2 diabetic patients in 16 weeks by oral hypoglycemic agents of Rosiglitazone(4~8mg,qd) and Repaglinide(1~4mg,tid).Results The results showed that there were significant decreases in FPG(4.98mmol/L),PG2H(8.05 mmol/L),GHbA1c(1.93%),FINS(11.0μU/ml) and LDL(0.12mmol/L) compared to those in pre-medication(P<0.001,P<0.05).None of hypoglycemic cases and abnormal hepatic and renal functions occurred(P>0.05).Conclusion Rosiglitazone and Repaglinide have the features and benefits of lowering plasma glucose,lipid,plasma insulin levels,also oral safety,excellent tolerability.
Keywords:Rosiglitazone  Repaglinide  Diabetes mellitus  Insulin resistance
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号